{"count": 2, "results": [{"_id": "25912112", "pmid": 25912112, "title": "Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study.", "journal": "Int J Cardiol", "authors": ["Chang SH", "Wu LS", "Lee CH", "Kuo CT", "Liu JR", "Wen MS", "Chen WJ", "See LC", "Yeh YH"], "date": "2015-01-01T00:00:00Z", "doi": "10.1016/j.ijcard.2015.04.121", "meta_date_publication": "2015", "meta_volume": "190", "meta_issue": "", "meta_pages": "20-5", "score": 50069.965, "text_hl": "@<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@Simvastatin-ezetimibe@@@ combination therapy is associated with a lower rate of @DISEASE_Epilepsy_Tonic_Clonic @DISEASE_MESH:D004830 @@@major@@@ adverse @DISEASE_Cardiovascular_Diseases @DISEASE_MESH:D002318 @@@cardiac events@@@ in @<m>DISEASE_Diabetes_Mellitus_Type_2</m> @DISEASE_MESH:D003924 @@@type 2 diabetics@@@ than high potency statins alone: A population-based dynamic cohort study.", "citations": {"NLM": "Chang SH, Wu LS, Lee CH, Kuo CT, Liu JR, Wen MS, Chen WJ, See LC, Yeh YH. Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study. Int J Cardiol. 2015;190():20-5. PMID: 25912112", "BibTeX": "@article{25912112, title={Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study.}, author={Chang SH and Wu LS and Lee CH and Kuo CT and Liu JR and Wen MS and Chen WJ and See LC and Yeh YH}, journal={Int J Cardiol}, volume={190}, pages={20-5}}"}}, {"_id": "21291712", "pmid": 21291712, "title": "Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes.", "journal": "J Clin Lipidol", "authors": ["Weinstock RS", "Goldberg RB", "Guyton JR", "Mazzone T", "Polis A", "Tomassini JE", "Lin J", "Shah A", "Tershakovec AM"], "date": "2008-02-01T00:00:00Z", "doi": "10.1016/j.jacl.2008.01.001", "meta_date_publication": "2008 Feb", "meta_volume": "2", "meta_issue": "1", "meta_pages": "25-35", "score": 50063.773, "text_hl": "CONCLUSION: @<m>CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination</m> @CHEMICAL_MESH:D000069499 @@@E/S@@@ provides a therapeutic option to @<m>DISEASE_Diabetes_Mellitus_Type_2</m> @DISEASE_MESH:D003924 @@@T2DM@@@ @SPECIES_9606 @@@patients@@@ for lowering not only LDL-C, but also non-HDL-C, @GENE_APOB @GENE_338 @@@ApoB@@@, and hs-CRP. ", "citations": {"NLM": "Weinstock RS, Goldberg RB, Guyton JR, Mazzone T, Polis A, Tomassini JE, Lin J, Shah A, Tershakovec AM. Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes. J Clin Lipidol. 2008 Feb;2(1):25-35. PMID: 21291712", "BibTeX": "@article{21291712, title={Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes.}, author={Weinstock RS and Goldberg RB and Guyton JR and Mazzone T and Polis A and Tomassini JE and Lin J and Shah A and Tershakovec AM}, journal={J Clin Lipidol}, volume={2}, number={1}, pages={25-35}}"}}]}